Research Pulse — 2026-09-02 | Brown Biotech

# Research Pulse — 2026-09-02
_Generated 2026-09-02 07:30 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 9월 2일 (수요일) · Maturation(성숙 Day)**

9/2(성숙) → 9/1(Converging) → 8/31(Standardizing) → 8/30(Industrializing) → 8/29(Sustaining) → 8/28(Accelerating) → 8/27(Catalyzing) → 8/26(Consolidating) → ... → 8/20(Expanding). Expanding(8/31)된 기술들이 **산업화·실용화 단계로 성숙(Maturation)하는 날** — Non-viral CRISPR delivery 136건 임상 trial 동시 진행 + 36건 in vivo에서 non-viral vector로의 뚜렷한 전환 확인(Lummerstorfer Drug Delivery 2026), 2026년 big pharma AI 플랫폼 대규모 투자 급증(Fay Lin GEN Biotechnology 2026), ROCKET으로 AlphaFold2 + cryo-EM/cryo-ET/X-ray 통합으로 실험 데이터-예측 구조 융합(Fadini Nature Methods 2026), CAPTAIN으로 4M cells + 382 proteins multimodal foundation model의 실용화(Ji Nature Communications 2026), 2025년 FDA protein kinase inhibitor 10개 신규 승인 + 2026 Q2-Q1 approval pipeline 확인(Roskoski Pharmacological Research 2026 + Joseph AJHP 2026), SCLC 원발/림프절 전이 CosMx spatial atlas 600K cells 구축(Zhang Cell Reports Medicine 2026), gastric cancer lymphocyte-aggregated region(LAR) 발견으로 immunotherapy biomarker 제시(Gao Nature Communications 2026)가 동시에 진행된다.

Maturation은 Expanding의 다음 단계다. 오늘 6개 전선은 확산된 기술들이 **산업화·실용화 단계로 성숙하는 날**이다.

*출처: [Lummerstorfer Non-Viral CRISPR Clinical Trials Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Fay Lin Pharma Bets Big AI 2026 GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Fadini ROCKET AlphaFold Cryo-EM Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Roskoski FDA Protein Kinase Inhibitors 2026 Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Joseph Novel Drug Approvals Q2 2026-Q1 2027 AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/), [Zhang SCLC Spatial Atlas Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)*

*#MaturationDay #NonViral #CRISPR #Lummerstorfer #DrugDelivery #136Trials #36InVivo #FayLin #AIBigPharma #GENBiotechnology #Fadini #ROCKET #AlphaFold #CryoEM #Ji #CAPTAIN #Multimodal #NatureCommunications #Roskoski #KinaseInhibitors #FDA2026 #Joseph #AJHP #NovelDrugPipeline #Zhang #SCLC #CosMx #600KCells #Gao #GastricCancer #LAR #Immunotherapy #Biomarker #Maturation #Expanding #Industrialization #ClinicalTranslation #SpatialAtlas #TME*

---

### Post 2: CRISPR & Gene Editing — Non-Viral CRISPR 136건 임상 + Precision Gene Editing 산업화

🧪 **[CRISPR/Gene Editing] Non-viral CRISPR delivery 136건 임상 trial 동시 진행 + 36건 in vivo에서 viral→non-viral vector 전환 확인(Lummerstorfer Drug Delivery 2026) + Precision gene editing이 proof-of-concept에서 curative therapies로 산업화 동시 진행(Cui Trends Molecular Medicine 2026) + CRISPR-Cas9 therapeutics 체계적review로 Casgevy 승인 landmark 확인(Chakraborty Molecular Therapy 2026): CRISPR의 산업화 성숙(Maturation) 동시 확인**

CRISPR 유전자 편집 기술의**산업화 성숙**이 출처에서 동시에 확인된다[1][2][3].

**Non-Viral CRISPR Clinical Trials: 136건 진행 + in vivo non-viral 전환加速[1]**
M. Lummerstorfer et al.(Drug Delivery 2026)의 review는 CRISPR 비바이러스성 전달 전략을 체계적으로 분석한다. **136건 CRISPR trials 진행 중**(2025년 12월 기준). **In vivo CRISPR 36건**: 비바이러스성 벡터로의 뚜렷한 전환 확인. **Non-viral delivery의 전략적 우위**: 게놈 편집의 영구적 특성상 장기간 CRISPR 기계 발현 불필요, 일시적 전달로도 lasting therapeutic effects 달성 가능. **"Hit-and-run" 접근법**: off-target 위험 감소. **Viral vectors의 기존 지위**: 유전자 보충 요법 시장의 지배적 지위 유지. **핵심 성숙 메시지**: in vivo CRISPR therapy에서 non-viral vectors로의 산업적 전환이 가속화 — Maturation 단계 도달. 핵심: Non-viral CRISPR 136건 trial 동시 진행 + 36건 in vivo non-viral vector 전환 확인 — CRISPR 산업화 Maturation.

**Precision Gene Editing: Proof-of-Concept에서 Curative Therapies 산업화[2]**
Tongtong Cui et al.(Trends in Molecular Medicine 2026)의 review는 정밀 유전자 편집 기술의 산업화를 분석한다. **기술 진화**: gene addition → precise genome editing 직접 돌연변이 교정으로. **핵심 플랫폼**: CRISPR-Cas nucleases, base editors, prime editors, CRISPR-associated transposases. **적용 범위**: ex vivo therapies → 중요 장기의 in vivo treatments. **N-of-1 medicine 실현**: carbamoyl phosphate synthetase 1 편집으로 rare disease 맞춤형 치료现身. **AI 통합**: editing tools 최적화 + outcomes 예측에 AI 적용. **Delivery & accessibility challenges**: 산업화 실현의 실질적 과제. 핵심: Precision gene editing의 curative therapies 산업화 — proof-of-concept에서 실용화 Maturation.

**CRISPR-Cas9 Therapeutics: Casgevy 승인 Landmark와 임상 Trials 현황[3]**
C. Chakraborty et al.(Molecular Therapy 2026)의 review는 CRISPR-Cas9 치료제 현황을 종합한다. **Casgevy 승인**: UK MHRA(2023년 11월 16일)가 transfusion-dependent β-thalassemia(TDT) 치료제로 최초 승인. 이후 sickle cell disease(SCD)도 승인 — FDA도 2023년 12월 8일 승인. **치료 개발 개요**: earliest days research → clinical trials → MHRA/FDA approved therapeutics. **Biopharmaceutical industry-academia collaboration**: 치료제 개발의 핵심 동력. **Patent landscape**: CRISPR-Cas9 기술의 지적재산권 체계. **Challenges**: safety concerns, cost-effectiveness — 시장 진입 장벽. 핵심: Casgevy 승인 landmark로 gene editing medicine의 시대 개막 — CRISPR 산업화 Maturation 완결.

**8월 31일 Converging Day vs 오늘의 차별점**: 8/31이 **Standardizing-Industrializing** 기술들을 제시했다면, 오늘은 **Lummerstorfer Drug Delivery**으로 **136건 trial 동시 진행 + non-viral vectors로의 산업적 전환**을(구체적产业化 지표), **Cui Trends Molecular Medicine**으로 **N-of-1 medicine实现 + AI 최적화 통합**을(curative therapies 산업화), **Chakraborty Molecular Therapy**으로 **Casgevy 승인 landmark 완결**을(监管 maturation) 동시에 제시한다. Converging → Maturation(9/2).

실무 함의: 유전자 치료 전달 기술팀에서 Lummerstorfer et al.의 non-viral trial 현황을 분석하여 임상 파이프라인 전략을 수립해야 한다.

*출처: [Lummerstorfer Non-Viral CRISPR Clinical Trials Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Cui Precision Gene Editing Trends Molecular Medicine 2026](https://consensus.app/papers/details/4aa70eeebc9c5bcbbf18360b17513b1b/), [Chakraborty CRISPR-Cas9 Therapeutics Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)*

*#CRISPR #GeneEditing #Lummerstorfer #DrugDelivery #NonViral #136Trials #36InVivo #HitAndRun #Cui #TrendsInMolecularMedicine #PrecisionGeneEditing #CurativeTherapies #Nof1 #Medicine #Chakraborty #MolecularTherapy #Casgevy #Cas9 #TDT #SCD #FDA #MHRA #MaturationDay #Industrialization #ClinicalTrials #GeneTherapy #BaseEditing #PrimeEditing #CRISPRassociatedTransposase #AIMolecularDesign*

---

### Post 3: AI 신약 — 2026 Big Pharma AI Deals 급증과 Industry Integration Maturation

💊 **[AI 신약] 2026년 big pharma AI 플랫폼 대규모 투자 급증 확인(Fay Lin GEN Biotechnology 2026) + AI drug discovery의 임상 이행 현황과 향후 전망 종합 확인(Seyhan Critical Reviews Oncology Hematology 2026) + AI-pharma collaboration model의 실용화 동시 진행(Ali Drug Development Research 2026): AI drug discovery의 산업화 성숙(Maturation) 동시 확인**

AI-Driven Drug Discovery의**산업화 성숙**이 출처에서 동시에 확인된다[4][5][6].

**2026 Pharma Bets Big on AI Platforms: Deal 급증[4]**
Fay Lin(GEN Biotechnology 2026)의 기사는 2026년 pharma의 AI 플랫폼 대규모 투자를 분석한다. **2026년 거래 급증**: Big pharma들이 AI 플랫폼에 대규모 투자 실행. **플랫폼 중심 전략**: 개별 약물 개발에서 AI 플랫폼 활용으로 패러다임 전환. **Industry integration 가속**: AI-pharma collaboration이 실용화 단계 진입. 핵심: 2026년 big pharma AI deals 급증으로 AI drug discovery의产业化 Maturation 도달.

**AI in Drug Discovery: 임상 이행 현황과 향후 전망[5]**
A. Seyhan et al.(Critical Reviews in Oncology/Hematology 2026)의 review는 AI drug discovery의 현재 상태를 종합한다. **변환 영역**: generative modeling으로 chemical/biological spaces 탐색 가속화, molecular interaction modeling 개선, therapeutic candidates 식별 최적화. **AI 플랫폼 현황**: scaffold-aware, 3D molecular design tools(AlphaFold, MoleR, PocketCrafter), single-cell foundation models, large language models(LLMs). **적용 범위**: target identification → drug discovery → lead optimization → phenotypic screening → precision biology 전 과정. **FDA 현황**: AI-enabled medical devices/numerous approvals — 그러나 fully AI-discovered/designed drug는 아직 0개 승인. **AI-originated candidates**: 임상 개발 진입으로 translational impact 입증. 핵심: AI drug discovery의 이행 현황 종합 —产业化 도달 아직不完全.

**AI in Drug Discovery: Pharmaceutical Innovation Transformation[6]**
M. Ali et al.(Drug Development Research 2026)의 review는 AI의 pharmaceutical innovation 변환을 분석한다. **ML/DL/NN의약학 적용**: target identification, hit finding, lead optimization, drug repurposing. **In-silico platforms**: toxicity, pharmacokinetics, developability 예측으로 late-stage attrition 감소. **Collaborative models**: AI developers + pharmaceutical industries 협업 모델. **Challenges**: algorithmic transparency, data quality, interoperability, regulatory acceptance. 핵심: AI-pharma collaborative model의 실용화 — Maturation 단계 진행.

**8월 31일 Converging Day vs 오늘의 차별점**: 8/31이 **Standardizing-Industrializing** 접근법을 제시했다면, 오늘은 **Fay Lin GEN Biotechnology**으로 **2026년 big pharma AI deals 급증**을(구체적产业化 지표), **Seyhan Critical Reviews**으로 **fully AI-discovered drug 0개 승인 현실**을(산업화 한계), **Ali Drug Development Research**으로 **AI-pharma collaborative model 실용화**를(Maturation 단계) 동시에 제시한다. Industrializing → Maturation(9/2).

실무 함의: AI drug discovery 협업팀에서 Fay Lin의 2026 deal 현황을 분석하여 partnership strategy를 수립해야 한다.

*출처: [Fay Lin Pharma Bets Big AI 2026 GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/)*

*#AI #DrugDiscovery #FayLin #GENBiotechnology #2026Deals #BigPharma #PlatformStrategy #Seyhan #CriticalReviews #OncologyHematology #Ali #DrugDevelopmentResearch #CollaborativeModel #MaturationDay #Industrialization #TranslationalImpact #ZeroAIApproval #LLM #AlphaFold #MoleR #PocketCrafter #FoundationModel #InSilico #ADMET #PharmaceuticalInnovation #AIPlatform*

---

### Post 4: 단백질 AI — ROCKET AlphaFold + Cryo-EM 융합과 AlphaFold3 산업 적용 확대

🔬 **[단백질 AI] ROCKET으로 AlphaFold2 + cryo-EM/cryo-ET/X-ray 통합으로 실험 데이터-예측 구조 융합 확인(Fadini Nature Methods 2026) + AlphaFold3의 architecture evolution과 산업 적용 종합 확인(Chakraborty Frontiers AI 2026) + AlphaFold comprehensive review로 practical applications 분석(Yin Frontiers Molecular Biosciences 2026): 단백질 AI의 산업화 성숙(Maturation) 동시 확인**

단백질 AI의**산업화 성숙**이 출처에서 동시에 확인된다[7][8][9].

**ROCKET: AlphaFold2 + Cryo-EM/ET/X-ray 통합으로 실험-예측 융합[7]**
A. Fadini et al.(Nature Methods 2026)의 연구는 ROCKET 방법을 제시한다. **문제**: AlphaFold2의 side-chain packing, condition-dependent conformational changes, biomolecular interactions modeling 한계. **ROCKET의 혁신**: cryo-EM, cryo-ET, X-ray crystallography 데이터를 AlphaFold2 예측 구조에 직접 통합. **방법**: coevolutionary embeddings 공간에서 구조 최적화 — Cartesian coordinates보다 biological structural variation 포착. **장점**: retraining 없이 scalable, automated model building. **적용**: experimental observables + biomolecular ML 통합의 범용 프레임워크. 핵심: ROCKET으로 AlphaFold + 실험 데이터 융합 — computational-experimental convergence Maturation.

**AlphaFold3 Architecture Evolution과 산업 적용 확대[8]**
C. Chakraborty et al.(Frontiers in Artificial Intelligence 2026)의 review는 AlphaFold의 architectural evolution과 산업 적용을 분석한다. **AF1→AF2→AF3 진화**: AF1(DNNs) → AF2(Evoformer, evolutionary information) → AF3(Pairformer, pairwise amino acid interactions). **AF3 확장**: protein-ligand, protein-nucleic acid, protein-protein complexes 예측. **AFDB**: AlphaFold Database로 구조 접근성 확대. **산업 적용**: structure-based drug discovery(SBDD), complex macromolecular assemblies 연구. **남은 도전**: protein dynamics, multiple conformational states 예측. 핵심: AlphaFold3의 산업 적용 확대 — 단백질 AI Maturation 도달.

**AlphaFold Comprehensive Review: Practical Applications 분석[9]**
Tianxiang Yin et al.(Frontiers in Molecular Biosciences 2026)의 review는 protein structure prediction의 practical applications를 분석한다. **배경**: X-ray crystallography, NMR, cryo-EM의 low throughput, high cost 한계. **Traditional computational methods 한계**: homologous templates 부재 시 poor performance. **AI-driven methods 우위**: near-experimental accuracy 달성. **주요 모델**: AlphaFold3, RoseTTAFold(accuracy), ESMFold(speed/scalability). **적용 분야**: drug discovery, enzyme engineering, disease research. 핵심: AlphaFold practical applications 종합 — 단백질 AI Maturation 완성.

**8월 31일 Converging Day vs 오늘의 차별점**: 8/31이 **Standardizing-Industrializing** 접근법을 제시했다면, 오늘은 **Fadini Nature Methods**으로 **ROCKET으로 cryo-EM/ET/X-ray-AF2 통합**을(실험-계산 융합 Maturation), **Chakraborty Frontiers AI**으로 **AlphaFold3의 architecture evolution + AFDB 산업 적용**을(산업화 Maturation), **Yin Frontiers Molecular Biosciences**으로 **AlphaFold/RoseTTAFold/ESMFold practical applications 종합**을(Maturation 완결) 동시에 제시한다. Industrializing → Maturation(9/2).

실무 함의: 전산단백질 설계팀에서 Fadini et al.의 ROCKET 접근법을 분석하여 computational-experimental integration strategy를 수립해야 한다.

*출처: [Fadini ROCKET AlphaFold Cryo-EM Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Chakraborty AlphaFold3 Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Yin AlphaFold Practical Applications Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)*

*#ProteinAI #AlphaFold #ROCKET #Fadini #NatureMethods #CryoEM #CryoET #XRay #AlphaFold2 #AlphaFold3 #Chakraborty #FrontiersAI #ArchitectureEvolution #Pairformer #Evoformer #Yin #FrontiersMolecularBiosciences #ESMFold #RoseTTAFold #DrugDiscovery #EnzymeEngineering #DiseaseResearch #MaturationDay #Industrialization #SBDD #AFDB #ProteinStructure #ComputationalBiology #Convergence #Automation*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — CAPTAIN Multimodal 산업 적용과 SCMBench Lightweight Adaptation

🬬 **[Single-Cell Multi-Omics Foundation Model] CAPTAIN으로 4M cells + 382 proteins multimodal foundation model의 산업 실용화 확인(Ji Nature Communications 2026) + SCMBench FMs vs DMs 격차 + lightweight adaptation bridging 재확인(Wang Nature Communications 2026) + Single-cell/spatial omics methods comprehensive review로 practical applications 종합(Cen MedComm 2026): foundation model의 산업화 성숙(Maturation) 동시 확인**

Single-Cell Foundation Model의**산업화 성숙**이 출처에서 동시에 확인된다[10][11][12].

**CAPTAIN: 4M Cells + 382 Proteins Multimodal Foundation Model 실용화[10]**
Boya Ji et al.(Nature Communications 2026)의 연구는 CAPTAIN multimodal foundation model을 제시한다. **기존 문제**: 현재 single-cell foundation models가 transcriptome만 훈련받아 biased/partial cellular state characterization. **CAPTAIN 혁신**: 4 million+ cells + 382 surface proteins 동시 측정. **Pretraining**: concurrently measured transcriptomes + curated proteins. **적용**: protein imputation/expansion, cell type annotation, batch harmonization. **COVID-19 발견**: immune interaction patterns linked to severity — novel hypothesis 생성 능력 입증. **Generalization**: fine-tuning + zero-shot settings 모두에서 robust performance. 핵심: CAPTAIN multimodal으로 4M+382 proteins 통합 — foundation model Maturation 도달.

**SCMBench: FMs vs DMs 격차 + Lightweight Adaptation Bridging 재확인[11]**
Yixuan Wang et al.(Nature Communications 2026)의 연구는 SCMBenchmark 결과를 재확인한다. **23 methods 평가**: integration accuracy, biomarker detection, trajectory inference, batch effect correction. **FMs < state-of-the-art DMs**: foundation models의 현 단계 한계 확인. **Lightweight adaptation**: performance gap bridging 가능. **핵심 메시지**: foundation models의 현재 한계 인식 + lightweight adaptation으로 실전 적용 가능. 핵심: SCMBench 결과 재확인 — FMs의 Maturation 단계 한계 인식.

**Single-Cell and Spatial Omics: Methods Comprehensive Review[12]**
Xiaoping Cen et al.(MedComm 2026)의 review는 single-cell/spatial omics의 practical applications를 종합한다. **기술Revolution**: bulk sequencing의 한계 극복, cellular heterogeneity + spatial organization Reveal. **주요 진전**: high-throughput, subcellular, multiomics profiling. **Computational advances**: generative AI, foundation models, multi-omics integration algorithms. **적용**: biomarker discovery, therapeutic target identification, precision medicine. **도전**: methodological advances vs systematic application 사이 격차. 핵심: single-cell/spatial omics methods 종합 — Maturation 전 단계.

**8월 31일 Converging Day vs 오늘의 차별점**: 8/31이 **Standardizing-Industrializing** 접근법을 제시했다면, 오늘은 **Ji Nature Communications**으로 **CAPTAIN 4M+382 proteins multimodal model의 산업 실용화**를(Maturation 도달), **Wang Nature Communications**으로 **SCMBench FMs< DMs 격차 + lightweight adaptation**을(Maturation 한계), **Cen MedComm**으로 **single-cell/spatial omics comprehensive review**를(Maturation 준비) 동시에 제시한다. Industrializing → Maturation(9/2).

실무 함의: 단일세포 연구팀에서 Ji et al.의 CAPTAIN multimodal 결과를 분석하여 protein-integrated foundation model strategy를 수립해야 한다.

*출처: [Ji CAPTAIN Multimodal Foundation Model Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single-Cell Spatial Omics MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)*

*#SingleCell #FoundationModel #CAPTAIN #Ji #NatureCommunications #Multimodal #4MillionCells #382Proteins #ProteinImputation #ZeroShot #Wang #SCMBench #FMsvsDMs #LightweightAdaptation #Cen #MedComm #SpatialOmics #MaturationDay #Industrialization #PrecisionMedicine #Biomarker #BatchHarmonization #COVID19 #ImmuneInteraction #FineTuning*

---

### Post 6: FDA/규제 — 2025년 10개 Kinase Inhibitor 승인과 2026 Q2-Q1 Approval Pipeline

📋 **[FDA/규제] 2025년 FDA protein kinase inhibitor 10개 신규 승인 확인(Roskoski Pharmacological Research 2026) + 2026 Q2-Q1 novel drug approvals pipeline 분석(Joseph AJHP 2026) + CRISPR therapeutics Casgevy 승인 완결(Chakraborty Molecular Therapy 2026): FDA/규제의 산업화 성숙(Maturation) 동시 확인**

FDA/규제의**산업화 성숙**이 출처에서 동시에 확인된다[13][14][15].

**2025년 FDA Protein Kinase Inhibitor 10개 승인: 94개 총 승인 현황[13]**
Robert Roskoski(Pharmacological Research 2026)의 review는 FDA 승인 protein kinase inhibitors 현황을 분석한다. **94개 총 승인**: 2025년 10개 신규 승인. **2025년 승인 약물**: avutometinib(MEK1/2, ovarian carcinoma), defactinib(FAK, low grade serous ovarian carcinoma), delgocitinib(JAK family, hand eczema), mirdametinib(MEK1/2, neurofibromatosis type I), remibrutinib(BTK, chronic spontaneous urticaria), rilzabrutinib(BTK, immune thrombocytopenia), sunvozertinib(mutant exon 21 EGFR, NSCLC), taletrectinib(mutant ROS1, NSCLC), vimseltinib(CSF1R, TGCT), zongertinib(mutant HER2, NSCLC). ** kinase classes**: dual specificity MEK1/2(6개), protein-serine/threonine(14개), nonreceptor tyrosine kinase(26개), receptor tyrosine kinase(48개). **80개** 경구 생물학적 이용 가능. **45개** Lipinski rule of five 위반. 핵심: 2025년 10개 kinase inhibitor 신규 승인 — FDA 규제 Maturation 확인.

**2026 Q2-Q1 Novel Drug Approvals Pipeline: 60개 신약 대기[14]**
R. Joseph et al.(AJHP 2026)의 review는 2026 Q2-2027 Q1 novel drug approvals pipeline를 분석한다. **60개 novel drugs FDA 승인 대기**. **pipeline 특징**: rare/inherited genetic disorders, immunologic/inflammatory diseases 치료제. ** continued advancements**: targeted oncology, gene therapies. **Health-system pharmacists 역할**: formulary management, resource allocation, clinical programs 최적화. **핵심**: novel therapies strengthening the pipeline — FDA Maturation 진행 중. 핵심: 2026년 60개 novel drugs 대기 pipeline — FDA 규제 Maturation 가속.

**CRISPR Therapeutics Maturation: Casgevy 완결[15]**
Chakraborty et al.(Molecular Therapy 2026)의 review는 Casgevy 완결을再確認한다. **TDT 최초 승인**: UK MHRA 2023년 11월. **SCD 승인**: FDA 2023년 12월. **치료제 개발 역사**: earliest research → clinical trials → regulatory approvals. **산업-학술 협력**: biopharmaceutical industry-academia collaboration의 핵심성. **Challenges**: safety concerns, cost-effectiveness — 시장 진입 현실. 핵심: Casgevy 완결으로 gene editing medicine 시대 개막 — 규제 Maturation 완성.

**8월 31일 Converging Day vs 오늘의 차별점**: 8/31이 **Standardizing-Industrializing** 규제 접근법을 제시했다면, 오늘은 **Roskoski Pharmacological Research**으로 **2025년 10개 kinase inhibitor 승인 + 94개 총 승인 현황**을(구체적 규제 Maturation 지표), **Joseph AJHP**으로 **2026 Q2-Q1 60개 novel drugs pipeline**을(FDA Maturation 가속), **Chakraborty Molecular Therapy**으로 **Casgevy 완결**을(규제 Maturation 완성) 동시에 제시한다. Industrializing → Maturation(9/2).

실무 함의: 규제 기획팀에서 Joseph et al.의 2026 pipeline 분석을 참조하여 novel drug regulatory strategy를 수립해야 한다.

*출처: [Roskoski FDA Protein Kinase Inhibitors 2026 Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Joseph Novel Drug Approvals Q2 2026-Q1 2027 AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/), [Chakraborty CRISPR-Cas9 Therapeutics Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)*

*#FDA #KinaseInhibitor #Roskoski #PharmacologicalResearch #2025Approvals #10NewDrugs #94Total #Avutometinib #Defactinib #Delgocitinib #Mirdametinib #Remibrutinib #Rilzabrutinib #Sunvozertinib #Taletrectinib #Vimseltinib #Zongertinib #Joseph #AJHP #NovelDrugPipeline #60Drugs #Q2Q1 #MaturationDay #GeneTherapy #CRISPR #Casgevy #TDT #SCD #Regulatory #TargetedOncology #GeneticDisorders #Immunology #Biomarker #Lipinski #OralBioavailability*

---

### Post 7: Spatial Transcriptomics — SCLC 600K Cells Atlas와 Gastric Cancer LAR Discovery

🗺️ **[Spatial Transcriptomics] SCLC 원발/림프절 전이 CosMx spatial atlas 600K cells 구축(Zhang Cell Reports Medicine 2026) + Gastric cancer lymphocyte-aggregated region(LAR) 발견으로 immunotherapy biomarker 제시(Gao Nature Communications 2026) + Pan-cancer spatial transcriptomics 12 cancer types 56 LCPs 확인(Li Cell Reports Medicine 2026): spatial transcriptomics의 산업화 성숙(Maturation) 동시 확인**

Spatial Transcriptomics의**산업화 성숙**이 출처에서 동시에 확인된다[16][17][18].

**SCLC Spatial Atlas: 600K Cells + 75 patients + CosMx[16]**
Zicheng Zhang et al.(Cell Reports Medicine 2026)의 연구는 SCLC의 spatial cellular ecosystem을 분석한다. **대상**: 75명 SCLC 환자, 105개 원발/림프절 전이 검체. **방법**: CosMx Spatial Molecular Imager. **규모**: 600,000+ cells의 comprehensive atlas. **주요 발견**: LNM-enriched malignant subclusters 3개( distinct metabolic/angiogenic programs). **공간적 상관관계**: immune exclusion features와 상관관계. **Vascular-immune crosstalk**: endothelial cells가 malignant cells 회피 + cytotoxic T cells와 functional perivascular niches 형성. **PIHs-1(pan-immune hotspot)**: 독립적 survival 예측 인자. 핵심: SCLC 600K cells spatial atlas 구축 — 공간적 TME 구조의 Maturation.

**Gastric Cancer LAR: Lymphocyte-Aggregated Region Immunotherapy Biomarker[17]**
Sen Gao et al.(Nature Communications 2026)의 연구는 gastric cancer의 spatial regions를 분석한다. **방법**: single-cell + spatial transcriptomics 통합. **4개 공간적 영역 발견**: 그 중 Lymphocyte Aggregated Region(LAR). **LAR 특성**: lymphocyte aggregates + tertiary lymphoid structures. **발견**: naive T cell abundance + T cell activation-associated pathways 상관관계. **A vs B group 차이**: Group A(더 활성화된 lymphocytes, 인접 종양세포)와 Group B(더 휴면 lymphocytes)의 차이. **PD1+CD27+ CD8 T cells**: CD70+LAMP3+ dendritic cells와 근접 클러스터. 핵심: Gastric cancer LAR 발견으로 immunotherapy biomarker 제시 — spatial TME의 Maturation.

**Pan-Cancer Spatial Transcriptomics: 12 Cancer Types 56 LCPs + 13 Recurrent Niches[18]**
Jiarong Li et al.(Cell Reports Medicine 2026)의 연구는 pan-cancer spatial transcriptomic analysis를 수행한다. **대상**: 12개 암종 373개 샘플. **56개 LCPs(Local Cellular Programs)**: 종양 미세환경의 국소 세포 프로그램. **13개 recurrent niches**: 종양 내 재발 nicho. **Ligand-receptor analysis**: niche-shared + niche-specific interactions 식별. **종양세포 + macrophages 의존성**: 위치에 따라 gene expression 상이. **Niche_4(종양-M2 macrophage colocalization)**: poor prognosis + immunotherapy resistance. **Niche_11(면역세포와 colocalization)**: better survival + treatment response. 핵심: Pan-cancer 12 types 56 LCPs spatial architecture 확립 — spatial TME Maturation 완성.

**8월 31일 Converging Day vs 오늘의 차별점**: 8/31이 **Standardizing-Industrializing** spatial transcriptomics 접근법을 제시했다면, 오늘은 **Zhang Cell Reports Medicine**으로 **SCLC 600K cells + 75 patients + CosMx atlas**를(대규모 실용화), **Gao Nature Communications**으로 **gastric cancer LAR discovery + immunotherapy biomarker**를(새 biology 발견), **Li Cell Reports Medicine**으로 **pan-cancer 12 types 56 LCPs + Niche_4/Niche_11 prognostic biomarkers**를(종합적 Maturation) 동시에 제시한다. Industrializing → Maturation(9/2).

실무 함의: spatial transcriptomics 연구팀에서 Li et al.의 Niche_4/Niche_11 prognostic biomarkers를 분석하여 immunotherapy response prediction strategy를 수립해야 한다.

*출처: [Zhang SCLC Spatial Atlas Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer LAR Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Spatial Transcriptomics Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#SpatialTranscriptomics #Zhang #CellReportsMedicine #SCLC #CosMx #600KCells #75Patients #LNM #PIH1 #Gao #NatureCommunications #GastricCancer #LAR #LymphocyteAggregatedRegion #TLS #PD1 #CD27 #CD8T #Li #PanCancer #12CancerTypes #56LCPs #13Niches #Niche4 #Niche11 #Macrophages #Prognosis #ImmunotherapyResistance #MaturationDay #SpatialAtlas #TME #SpatialArchitecture #Biomarker #Survival #TreatmentResponse*

---

### Post 8: 오늘의 요약 — Maturation(성숙 Day) 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

9/2(Maturation)의 핵심: Expanding(8/31)된 기술들이 **산업화·실용화 단계로 성숙(Maturation)하는 날**이었다.

**1. Non-Viral CRISPR 136건 Clinical Trials 동시 진행(Lummerstorfer Drug Delivery 2026)**: 36건 in vivo에서 viral→non-viral vector 전환 확인 + "hit-and-run" 접근법으로 off-target 감소 — CRISPR 산업화 Maturation. [Lummerstorfer Drug Delivery 2026]

**2. 2026 Big Pharma AI Deals 급증(Fay Lin GEN Biotechnology 2026)**: Pharma Bets Big on AI Platforms — AI drug discovery의产业化 Maturation 가속. [Fay Lin GEN Biotechnology 2026]

**3. ROCKET AlphaFold2 + Cryo-EM/ET/X-ray 통합(Fadini Nature Methods 2026)**: 실험 데이터-예측 구조 융합으로 computational-experimental convergence Maturation 도달. [Fadini Nature Methods 2026]

**4. CAPTAIN 4M Cells + 382 Proteins Multimodal Model(Ji Nature Communications 2026)**: transcriptome-only 제한 극복 + protein-integrated foundation model 산업 실용화 — scFM Maturation 도달. [Ji Nature Communications 2026]

**5. 2025년 FDA Kinase Inhibitor 10개 신규 승인(Roskoski Pharmacological Research 2026)**: 94개 총 승인 + 2026 Q2-Q1 60개 novel drugs pipeline — FDA 규제 Maturation 가속. [Roskoski Pharmacological Research 2026]

**6. SCLC 600K Cells Spatial Atlas(Zhang Cell Reports Medicine 2026) + Gastric Cancer LAR Discovery(Gao Nature Communications 2026) + Pan-Cancer 12 Types 56 LCPs(Li Cell Reports Medicine 2026)**: 대규모 spatial atlas + immunotherapy biomarker 확립 — spatial TME Maturation 완성. [Zhang Cell Reports Medicine 2026; Gao Nature Communications 2026; Li Cell Reports Medicine 2026]

**9월 3일 전망**: Maturation된 기술들의 산업화 속도와 실용화采纳가 핵심 변수. 특히 non-viral CRISPR의 36건 in vivo trial 임상 결과, ROCKET의 실험실 적용 확대, CAPTAIN의 zero-shot applications 확대, Niche_4/Niche_11의 임상 validation이 관전.

*출처: [Lummerstorfer Non-Viral CRISPR Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/), [Cui Precision Gene Editing Trends Molecular Medicine 2026](https://consensus.app/papers/details/4aa70eeebc9c5bcbbf18360b17513b1b/), [Chakraborty CRISPR-Cas9 Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/), [Fay Lin Pharma AI 2026 GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/), [Seyhan AI Drug Discovery Critical Reviews 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Ali AI Drug Discovery Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/), [Fadini ROCKET Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/), [Chakraborty AlphaFold3 Frontiers AI 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/), [Yin AlphaFold Frontiers Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Wang SCMBench Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/), [Cen Single-Cell Spatial MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/), [Roskoski Kinase Inhibitors Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/), [Joseph Novel Drug Approvals AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/), [Zhang SCLC Spatial Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/), [Gao Gastric Cancer Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/), [Li Pan-Cancer Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)*

*#MaturationDay #Summary #Lummerstorfer #NonViral #CRISPR #136Trials #FayLin #AIBigPharma #Fadini #ROCKET #CryoEM #Ji #CAPTAIN #Multimodal #382Proteins #Roskoski #KinaseInhibitor #2025 #Joseph #NovelDrugPipeline #60Drugs #Zhang #SCLC #600K #Gao #LAR #GastricCancer #Li #PanCancer #56LCPs #Niche4 #Niche11 #Maturation #Industrialization #ClinicalTranslation #PrecisionMedicine #SpatialAtlas #TME #Biomarker #Prognosis #Immunotherapy*

---

## Sources

[1] [Lummerstorfer et al. — Non-Viral CRISPR carriers: transient delivery with lasting effects. Drug Delivery 2026](https://consensus.app/papers/details/747d35e9e5bc5ca9a9854998c7acd326/)
[2] [Cui et al. — Precision gene editing: From proof-of-concept to curative therapies. Trends in Molecular Medicine 2026](https://consensus.app/papers/details/4aa70eeebc9c5bcbbf18360b17513b1b/)
[3] [Chakraborty et al. — CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases. Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)
[4] [Fay Lin — Pharma Bets Big on AI Platforms with Flurry of 2026 Deals. GEN Biotechnology 2026](https://consensus.app/papers/details/bc6e9ea3ec2e5025af707131d2fa0ca7/)
[5] [Seyhan et al. — AI in Drug Discovery and Development. Critical Reviews in Oncology/Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)
[6] [Ali et al. — Artificial Intelligence in Drug Discovery and Development: Transforming Pharmaceutical Innovation. Drug Development Research 2026](https://consensus.app/papers/details/7a8e73e032a7505fa67758810d3c03ec/)
[7] [Fadini et al. — AlphaFold as a prior: experimental structure determination conditioned on a pretrained neural network. Nature Methods 2026](https://consensus.app/papers/details/a1a4ffbc5dd75c548e55837812a33916/)
[8] [Chakraborty et al. — The transformative impact of AI-enabled AlphaFold 3: evolution, current status, and future prospects in structural biology. Frontiers in Artificial Intelligence 2026](https://consensus.app/papers/details/34db0d4f32255b8696144613f6182df8/)
[9] [Yin et al. — Protein structure prediction powered by artificial intelligence: from biochemical foundations to practical applications. Frontiers in Molecular Biosciences 2026](https://consensus.app/papers/details/880e72fce35255c4887811c76849c03a/)
[10] [Ji et al. — CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
[11] [Wang et al. — SCMBench: benchmarking domain-specific and foundation models for single-cell multi-omics data integration. Nature Communications 2026](https://consensus.app/papers/details/24b273d01c1f508c9a20a5a981ac2e3c/)
[12] [Cen et al. — Single-Cell and Spatial Omics: Methods and Applications. MedComm 2026](https://consensus.app/papers/details/c4f998ebe8e15bf498b5fb58997799d6/)
[13] [Roskoski — Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. Pharmacological Research 2026](https://consensus.app/papers/details/a1931950cc815d8a9136ea7cea0912f3/)
[14] [Joseph et al. — Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027). AJHP 2026](https://consensus.app/papers/details/f0ba74eec6e152cabf53cd17e507d654/)
[15] [Chakraborty et al. — CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases. Molecular Therapy 2026](https://consensus.app/papers/details/68148f0062ec554ba4af1996dd3718cb/)
[16] [Zhang et al. — Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer. Cell Reports Medicine 2026](https://consensus.app/papers/details/dc8b02ddbfcb574fb92b18cf8aed1117/)
[17] [Gao et al. — A spatially resolved atlas of gastric cancer characterises a lymphocyte-aggregated region. Nature Communications 2026](https://consensus.app/papers/details/46f3d71acd2e5b6e8816d6886aa485d9/)
[18] [Li et al. — Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine 2026](https://consensus.app/papers/details/f420ab985e1257e18352cac9e0c425cf/)